| Name | Title | Contact Details |
|---|---|---|
Nick Crowe |
Chief Operating Officer | Profile |
Michelle Wong |
Chief Operating Officer | Profile |
Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.
Trovagene is a molecular diagnostics company providing precise, noninvasive urine and blood testing for detecting and monitoring oncogene mutations. By utilizing proprietary technology that analyzes circulating tumor DNA, Trovagene testing offers critical data that may help inform cancer treatment decisions, giving physicians and patients monitoring options beyond biopsy or imaging.
Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune and blood based diseases.
AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.
Setren, Smallberg and Associates is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.